Literature DB >> 479347

A solid phase, sandwich-type radioimmunoassay for antithyroglobulin: elimination of false positive results and semiquantitative measurement of antithyroglobulin in the presence of elevated thyroglobulin.

M F Bayer, J P Kriss.   

Abstract

Thyroid disorders can be associated with elevated concentrations of serum antithyroglobulin antibodies (anti-Tg) and/or thyroglobulin (Tg), but none of the available anti-Tg assays deals with anti-Tg measurements in the presence of abnormally high Tg levels. The competitive binding radioassay produces falsely elevated values for anti-Tg if serum Tg is elevated and either falsely elevated or depressed values if both Tg and anti-Tg are abnormally high. The falsely elevated anti-Tg values can be identified by measuring the formation of Tg[125I]anti-Tg complexes in the supernatant of the anti-Tg assay (supernatant assay). For screening purposes, we modified the original anti-Tg RIA into a solid phase, sandwich-type RIA. Anti-Tg in serum or standard is first bound to plastic cups coated with Tg and then quantitated by binding of [125I]Tg. This assay has a detection limit of 2 U/ml serum, intra- and interassay coefficients of variation of 9--15%, and a normal range of less than 2 U/ml. When sera with normal Tg concentrations were analyzed, the results for anti-Tg obtained by the competitive binding RIA and the new sandwich RIA were comparable as far as positives and negatives were concerned, and the numerical values for positive sera correlated moderately well (r = 0.79); the sandwich assay, in general, gave lower values for anti-Tg. The major advantages of the sandwich anti-Tg RIA are the elimination of false positive results and its applicability to sera containing high levels of both Tg and anti-Tg. In the latter case, the results indicate the level of free anti-Tg present, as opposed to antibody present in the form of Tg-anti-Tg complexes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 479347     DOI: 10.1210/jcem-49-4-565

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Serum thyroglobulin (Tg) in presence of thyroglobulin autoantibodies (TgAb). Clinical and methodological relevance of the interaction between Tg and TgAb in vitro and in vivo.

Authors:  U Feldt-Rasmussen; A K Rasmussen
Journal:  J Endocrinol Invest       Date:  1985-12       Impact factor: 4.256

2.  L-thyroxine therapy induces a fall of thyroid microsomal and thyroglobulin antibodies in idiopathic myxedema and in hypothyroid, but not in euthyroid Hashimoto's thyroiditis.

Authors:  L Chiovato; C Marcocci; S Mariotti; A Mori; A Pinchera
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

3.  A new solid-phase immunoradiometric assay for anti-thyroglobulin autoantibody.

Authors:  S Mariotti; S Pisani; A Russova; A Pinchera
Journal:  J Endocrinol Invest       Date:  1982 Jul-Aug       Impact factor: 4.256

4.  The measurement of antithyroglobulin autoantibodies in the presence of thyroglobulin.

Authors:  A J Henniker; B M Luttrell; P Ward; J N Stiel; E G Wilmshurst
Journal:  J Endocrinol Invest       Date:  1983-08       Impact factor: 4.256

5.  The influence of subtotal thyroidectomy on the thyroglobulin binding capacity of thyrotoxic serum.

Authors:  T J Wilkin; J S Beck; A Gunn; R Potts; R J Young
Journal:  J Endocrinol Invest       Date:  1980 Oct-Dec       Impact factor: 4.256

6.  Changes of circulating thyroid autoantibody levels during and after the therapy with methimazole in patients with Graves' disease.

Authors:  C Marcocci; L Chiovato; S Mariotti; A Pinchera
Journal:  J Endocrinol Invest       Date:  1982 Jan-Feb       Impact factor: 4.256

7.  Utility of Thyroglobulin measurement in fine-needle aspiration biopsy specimens of lymph nodes in the diagnosis of recurrent thyroid carcinoma.

Authors:  Zubair W Baloch; Julieta E Barroeta; Janet Walsh; Prabodh K Gupta; Virginia A Livolsi; Jill E Langer; Susan J Mandel
Journal:  Cytojournal       Date:  2008-01-31       Impact factor: 2.091

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.